Abstract | BACKGROUND: METHODS: RESULTS: Two patients could not tolerate the medication. After one month of therapy, 16 patients (64%) reported a reduction in fatigue on the Hare fatigue scale; three of 16 showed improvement on the modified Barthel index for activities of daily living, and two of 16 experienced improvement on a modified Klingman mobility index. Pyridostigmine responders were significantly more fatigued than non-responders on the pre-treatment Hare score, but were not significantly different with regard to age, sex, age at acute poliomyelitis, or severity of acute poliomyelitis. CONCLUSIONS:
|
Authors | D A Trojan, N R Cashman |
Journal | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
(Can J Neurol Sci)
Vol. 22
Issue 3
Pg. 223-7
(Aug 1995)
ISSN: 0317-1671 [Print] England |
PMID | 8529175
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Age of Onset
- Aged
- Fatigue
(drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Motor Activity
(drug effects)
- Postpoliomyelitis Syndrome
(drug therapy)
- Pyridostigmine Bromide
(therapeutic use)
- Treatment Outcome
|